MA46292A - Réglage de dose - Google Patents

Réglage de dose

Info

Publication number
MA46292A
MA46292A MA046292A MA46292A MA46292A MA 46292 A MA46292 A MA 46292A MA 046292 A MA046292 A MA 046292A MA 46292 A MA46292 A MA 46292A MA 46292 A MA46292 A MA 46292A
Authority
MA
Morocco
Prior art keywords
dose setting
dose
setting
Prior art date
Application number
MA046292A
Other languages
English (en)
Inventor
Sandeep Dutta
Matthew Kosloski
Wei Liu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MA46292A publication Critical patent/MA46292A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046292A 2016-09-23 2017-09-22 Réglage de dose MA46292A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398724P 2016-09-23 2016-09-23
US201762510936P 2017-05-25 2017-05-25

Publications (1)

Publication Number Publication Date
MA46292A true MA46292A (fr) 2019-07-31

Family

ID=61687385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046292A MA46292A (fr) 2016-09-23 2017-09-22 Réglage de dose

Country Status (10)

Country Link
US (1) US20180085330A1 (fr)
EP (1) EP3515442A4 (fr)
JP (2) JP2019529426A (fr)
CN (1) CN109715161A (fr)
AU (2) AU2017332771A1 (fr)
BR (1) BR112019005725A2 (fr)
CA (1) CA3037719A1 (fr)
MA (1) MA46292A (fr)
MX (1) MX394461B (fr)
WO (1) WO2018057919A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124384A2 (fr) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Méthodes de traitement de l'hépatite c
WO2011009961A1 (fr) * 2009-07-24 2011-01-27 Virologik Gmbh Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
JP2014533659A (ja) * 2011-10-24 2014-12-15 アッヴィ・インコーポレイテッド スクレロスチンに対するイムノバインダー
KR20210013344A (ko) * 2013-03-14 2021-02-03 애브비 인코포레이티드 C형 간염 치료용 2가지 항바이러스제의 병용물
TW202002979A (zh) * 2013-03-14 2020-01-16 美商艾伯維有限公司 治療hcv的方法
CN106413711A (zh) * 2014-04-02 2017-02-15 艾伯维公司 治疗hcv的方法
WO2016140615A1 (fr) * 2015-03-02 2016-09-09 Medivir Ab Dérivés nucléotidiques qui sont des inhibiteurs du vhc pour une utilisation dans le traitement de l'hépatite c
AU2016216673B2 (en) * 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds

Also Published As

Publication number Publication date
JP2019529426A (ja) 2019-10-17
EP3515442A1 (fr) 2019-07-31
EP3515442A4 (fr) 2020-05-06
JP2022153655A (ja) 2022-10-12
CN109715161A (zh) 2019-05-03
AU2022202895A1 (en) 2022-05-26
MX394461B (es) 2025-03-24
US20180085330A1 (en) 2018-03-29
MX2019003366A (es) 2019-07-04
AU2017332771A1 (en) 2019-04-04
WO2018057919A1 (fr) 2018-03-29
CA3037719A1 (fr) 2018-03-29
BR112019005725A2 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
EP3463464A4 (fr) Traitement d'association
DK3405050T3 (da) Børnesikret snusbeholder
EP3440949A4 (fr) Inhalateur d'arôme
EP3446605A4 (fr) Aspirateur à main
DK3310231T3 (da) Doseringsindretning
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
EP3424940A4 (fr) Médicament radiomarqué
DK3402792T3 (da) Quinolin-2-on-derivater
DK3445708T3 (da) Stigbøjle
EP3402022A4 (fr) Pince-fil
EP3402021A4 (fr) Pince-fil
IL262851A (en) Combination prime: boost therapy
DK3509963T3 (da) Pallecontainer
DK3393478T3 (da) Kombinationsterapi
EP3437644A4 (fr) Médicament
EP3362091A4 (fr) Polythérapie
DK3452590T3 (da) Plademagnet
DK3575238T3 (da) Pallecontainer
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
EP3443854A4 (fr) Inhalateur d'arôme
EP3399976C0 (fr) Amphophiles de benzothiazole
EP3455282A4 (fr) Fluides hydrauliques à base de polysiloxane
EP3527216A4 (fr) Médicament
DE112017000734A5 (de) Glycolsensor